Strategic Goals and Objectives for 2015-2020

The RESIST-TB Strategic Goals and Objectives for 2015-2020 are the result of a strategic planning process, culminating in a meeting held in Barcelona on October 29th, 2014. This meeting was attended by Steering Committee Members Carole Mitnick, Bob Horsburgh, Salim Hamid, Christian Lienhardt, Frank Cobelens, Salmaan Keshavjee, Grania Brigden, and RESIST-TB Staff Member Carly Rodriguez.

Goal I. Accelerate uptake of effective, scalable regimens for MDR-TB treatment

Objective 1: Facilitate and promote field trials of regimens with new agents

Objective 2: Develop new approaches to demonstrating effectiveness of potential MDR-TB treatment regimens utilizing Phase 2 and observational cohort data

Objective 3: Promote dialogue with regulatory agencies regarding new trial designs to enable timely approval of scalable regimens.

Objective 4: Provide information for clinicians/programs on how to use these scalable regimens

Objective 5: Collect data documenting success in getting new regimens into programmatic use

Goal II. Advocate for clinical trials of preventive therapy for MDR-TB

Objective 1: Facilitate and promote observational cohort designs, pilot trials and full trials to address MDR-TB preventive therapy

Objective 2: Review animal model data supporting use of new agents for preventive therapy

Goal III. Optimize communication between stakeholders in the MDR-TB community

Objective 1: Advance dialogue about strategies for accelerating MDR-TB treatment roll-out

Objective 2: Identify opportunities for increasing communication between stakeholders

Objective 3: Maintain role as independent broker on MDR-TB issues